Sanne C.F.A. Huijberts

An Acquired Vulnerability of Drug-Resistant Melanoma with Therapeutic Potential

Liqin Wang, Rodrigo Leite de Oliveira, Sanne C.F.A. Huijberts et al. · Cell · 2018 · 336 citations · Full text

Tumor Biology, Acquired Vulnerability, Medicine +7

Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With <i>BRAF</i> V600E–Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study

Eric Van Cutsem, Sanne C.F.A. Huijberts, Axel Grothey et al. · Journal of Clinical Oncology · 2019 · 222 citations · Full text

Oncology, Cancer Epidemiology, Safety Lead-in Results +13

Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer

Robin M.J.M. van Geel, Emilie M.J. van Brummelen, Ferry A.L.M. Eskens et al. · British Journal of Cancer · 2020 · 47 citations · Full text

Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancer

Sanne C.F.A. Huijberts, Robin M.J.M. van Geel, Emilie M.J. van Brummelen et al. · Cancer Chemotherapy and Pharmacology · 2020 · 41 citations

Kras-mutant Colorectal, Pancreatic Cancer, Gastrointestinal Oncology +9

BEACON CRC study safety lead-in (SLI) in patients with <i>BRAF</i>^V600E metastatic colorectal cancer (mCRC): Efficacy and tumor markers.

Eric Van Cutsem, Pieter‐Jan Cuyle, Sanne C.F.A. Huijberts et al. · Journal of Clinical Oncology · 2018 · 37 citations

Cancer Management, Immunology, Pathology +16